Skip to content
Subscriber Only
Max Nisen

Valeant Is Poised to Disappoint

A look at prescription data suggests its guidance is unrealistic.

Valeant seems to be better at boosting drug prices than its own stock price.

The embattled specialty pharma firm's shares have tumbled 28 percent from a peak of more than $31 in August. That month, the company enjoyed a string of rare positive headlines, including a 2016 revenue forecast that surprised investors by holding steady instead of being cut for the umpteenth time.